COVID-19: INCREASING NUMBERS OF REPORTS ON ISCHEMIC STROKE AND INCREASED THROMBOEMBOLIC RISK

COVID-19: INCREASING NUMBERS OF REPORTS ON ISCHEMIC STROKE AND INCREASED THROMBOEMBOLIC RISK

AURA Biopharm AS is in the preclinical phase of developing AUR-1001, a first in class pathogenic-tailored drug for the prevention of thrombosis in patients with Antiphospholipid syndrome (APS). In many reports lupus anticoagulant (LAC) and antiphospholipid antibodies (APAb) are reported positive on Covid-19 patients with hyper-coagulation state, A PARTICULARLY SEVERE PRESENTATION OF THE DISEASE. The company has begun studies to elucidate the role of APAb in Covid-19 patients and how AUR-1001 can be developed as a treatment of such serious viral infections with coagulopathy and antiphospholipid antibodies.